药品市场中的监管家长主义：来自万络和西乐葆的教训。 - Suppr

Suppr

超能文献

Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.

作者信息

Epstein Richard A

机构信息

The University of Chicago, USA.

出版信息

Yale J Health Policy Law Ethics. 2005 Summer;5(2):741-70.

PMID:16052898

Abstract

摘要

相似文献

Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.

Yale J Health Policy Law Ethics. 2005 Summer;5(2):741-70.

Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.

J Natl Cancer Inst. 2005 Apr 20;97(8):552-3. doi: 10.1093/jnci/97.8.552.

Drug safety. FDA panel urges caution on many anti-inflammatory drugs.

Science. 2005 Feb 25;307(5713):1183-5. doi: 10.1126/science.307.5713.1183a.

Raising the safety bar--the FDA's coxib meeting.

N Engl J Med. 2005 Mar 31;352(13):1283-5. doi: 10.1056/NEJMp058055.

The COX-2 inhibitors--an update.

Am Heart J. 2006 Aug;152(2):197-9. doi: 10.1016/j.ahj.2006.05.022.

The problem of new uses.

Yale J Health Policy Law Ethics. 2005 Summer;5(2):717-39.

How to avoid another 'Vioxx'.

Nat Rev Drug Discov. 2005 Jan;4(1):5-7. doi: 10.1038/nrd1629.

The lessons of Vioxx--drug safety and sales.

N Engl J Med. 2005 Jun 23;352(25):2576-8. doi: 10.1056/NEJMp058136.

Vioxx doctors wooed by Merck are now its foes.

Wall St J (East Ed). 2006 Mar 10:B1, B3.

The vexations of Vioxx.

CMAJ. 2006 Feb 14;174(4):444-5. doi: 10.1503/cmaj.060041.

引用本文的文献

Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.

Biomedicines. 2016 Nov 21;4(4):27. doi: 10.3390/biomedicines4040027.

Can a good tree bring forth evil fruit? The funding of medical research by industry.

Br Med Bull. 2016 Jun;118(1):5-15. doi: 10.1093/bmb/ldw014. Epub 2016 May 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.

Yale J Health Policy Law Ethics. 2005 Summer;5(2):741-70.

Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.

J Natl Cancer Inst. 2005 Apr 20;97(8):552-3. doi: 10.1093/jnci/97.8.552.

Drug safety. FDA panel urges caution on many anti-inflammatory drugs.

Science. 2005 Feb 25;307(5713):1183-5. doi: 10.1126/science.307.5713.1183a.

Raising the safety bar--the FDA's coxib meeting.

N Engl J Med. 2005 Mar 31;352(13):1283-5. doi: 10.1056/NEJMp058055.

The COX-2 inhibitors--an update.

Am Heart J. 2006 Aug;152(2):197-9. doi: 10.1016/j.ahj.2006.05.022.

The problem of new uses.

Yale J Health Policy Law Ethics. 2005 Summer;5(2):717-39.

How to avoid another 'Vioxx'.

Nat Rev Drug Discov. 2005 Jan;4(1):5-7. doi: 10.1038/nrd1629.

The lessons of Vioxx--drug safety and sales.

N Engl J Med. 2005 Jun 23;352(25):2576-8. doi: 10.1056/NEJMp058136.

Vioxx doctors wooed by Merck are now its foes.

Wall St J (East Ed). 2006 Mar 10:B1, B3.

The vexations of Vioxx.

CMAJ. 2006 Feb 14;174(4):444-5. doi: 10.1503/cmaj.060041.

引用本文的文献

Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.

Biomedicines. 2016 Nov 21;4(4):27. doi: 10.3390/biomedicines4040027.

Can a good tree bring forth evil fruit? The funding of medical research by industry.

Br Med Bull. 2016 Jun;118(1):5-15. doi: 10.1093/bmb/ldw014. Epub 2016 May 5.